L
Laura D. Locati
Researcher at University of Milan
Publications - 192
Citations - 6143
Laura D. Locati is an academic researcher from University of Milan. The author has contributed to research in topics: Cancer & Head and neck cancer. The author has an hindex of 35, co-authored 170 publications receiving 4810 citations. Previous affiliations of Laura D. Locati include University of Gothenburg.
Papers
More filters
Journal ArticleDOI
High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma
Lisa Licitra,Federica Perrone,Paolo Bossi,Simona Suardi,Luigi Mariani,Raffaella Artusi,Maria Oggionni,Chiara Rossini,Giulio Cantù,Massimo Squadrelli,Pasquale Quattrone,Laura D. Locati,Cristiana Bergamini,Patrizia Olmi,Marco A. Pierotti,Silvana Pilotti +15 more
TL;DR: The molecular and clinical results are in agreement with previous findings but provide additional information into the biologic mechanisms involved in HR-HPV oropharyngeal cancer in comparison to HPV-negative tumors.
Journal ArticleDOI
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Sebastiano Filetti,Cosimo Durante,D. Hartl,D. Hartl,Sophie Leboulleux,Sophie Leboulleux,Laura D. Locati,Kate Newbold,Mauro Papotti,Alfredo Berruti +9 more
TL;DR: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Department of Head and Neck Oncology, Gustave Roussy, Villejuif; Université Paris Saclay, Villeroy-sur-Sierre, France; and Department of Nuclear Medicine and Endocrine Oncological Sciences and Public Health, University of Brescia.
Journal ArticleDOI
Major and minor salivary gland tumors
TL;DR: Surgery, irradiation or re-irradiation are treatment options for local relapse, whereas radical neck dissection is indicated for regional relapses, and the employment of anti-androgen therapy is indicated.
Journal ArticleDOI
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin Schlumberger,Rossella Elisei,Lars Bastholt,Lori J. Wirth,Renato G. Martins,Laura D. Locati,Barbara Jarzab,Furio Pacini,Chantal Daumerie,Jean Pierre Droz,Michael Eschenberg,Yu Nien Sun,Todd Juan,Daniel E. Stepan,Steven I. Sherman +14 more
TL;DR: Although the objective response rate was low, a significant proportion of MTC patients (81%) achieved stable disease while receiving motesanib, and motesanIB trough concentrations were lower compared with differentiated thyroid cancer patients from the same study.
Journal ArticleDOI
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Laura D. Locati,Paolo Bossi,Federica Perrone,Paolo Potepan,F. Crippa,Luigi Mariani,Paola Casieri,Marta Orsenigo,Marco Losa,Cristiana Bergamini,C. Liberatoscioli,Pasquale Quattrone,Rosa Gioia Calderone,G. Rinaldi,S. Pilotti,Lisa Licitra +15 more
TL;DR: In RMSGCs further evaluations of EGFR targeting agents are advisable and should take place by appropriate tumor biological selection, differentiating ACC from non-ACC.